生物制药公司Travere Therapeutics(TVTX)股价当日盘中大涨5.91%,投资者对公司研发的罕见肾病新药sparsentan的前景看好。
Travere Therapeutics专注于为患有罕见肾脏、肝脏和代谢疾病的人研发新药。其在研新药sparsentan是治疗局灶节段性肾小球硬化症(FSGS)和IgA肾病的后期候选药物,如果顺利获批上市,将为公司带来重大利好。
虽然公司目前净利润为负,但营收和毛利较高,处于盈利前投入期正常状态。机构对其未来发展前景看好,93%机构给予买入评级,只有7%持有评级,无卖出评级。投资者看好sparsentan获批并推动公司业绩大幅增长的预期,推动了当日股价大涨超5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.